GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peak Bio Inc (OTCPK:PKBO) » Definitions » Interest Coverage

Peak Bio (Peak Bio) Interest Coverage : 0 (At Loss) (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Peak Bio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Peak Bio's Operating Income for the three months ended in Jun. 2023 was $-2.67 Mil. Peak Bio's Interest Expense for the three months ended in Jun. 2023 was $-1.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Peak Bio's Interest Coverage or its related term are showing as below:


PKBO's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Peak Bio Interest Coverage Historical Data

The historical data trend for Peak Bio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Peak Bio Interest Coverage Chart

Peak Bio Annual Data
Trend Dec21 Dec22
Interest Coverage
- -

Peak Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Interest Coverage Get a 7-Day Free Trial No Debt No Debt - - -

Competitive Comparison of Peak Bio's Interest Coverage

For the Biotechnology subindustry, Peak Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peak Bio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peak Bio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Peak Bio's Interest Coverage falls into.



Peak Bio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Peak Bio's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, Peak Bio's Interest Expense was $-0.05 Mil. Its Operating Income was $-11.85 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.51 Mil.

Peak Bio did not have earnings to cover the interest expense.

Peak Bio's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Here, for the three months ended in Jun. 2023, Peak Bio's Interest Expense was $-1.00 Mil. Its Operating Income was $-2.67 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Peak Bio did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Peak Bio  (OTCPK:PKBO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Peak Bio Interest Coverage Related Terms

Thank you for viewing the detailed overview of Peak Bio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Peak Bio (Peak Bio) Business Description

Traded in Other Exchanges
N/A
Address
4900 Hopyard Road, Suite 100, Pleasanton, CA, USA, 94588
Peak Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology and inflammation.
Executives
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Michael R. Friedman director 245 E. 58TH STREET, APT #15B, NEW YORK NY 10022
Peter David Mccabe officer: General Counsel 584 CASTRO STREET, #882, SAN FRANCISCO CA 94114
Sbi Kis 2016-1 Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO GANGNAM, SEOUL M5 00000
2014 Kif-sbi It Investment Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
2019 Sbi Job Creation Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Investment Korea Co., Ltd. 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Healthcare Fund I 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Sbi Cross-border Advantage Fund 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Bio Fund 1 Ikbc-sbi 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Gateway Fund 1 Global 10 percent owner 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM, SEOUL M5 00000
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Satyajit Kumar Mitra officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Stephen J Lamond director, officer: See Remarks 3350 W BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
David I. Rosenberg director C/O IGNYTE ACQUISITION CORP., 640 5TH AVENUE, 4TH FLOOR, NEW YORK NY 10019